CN103130710B - Anti-enteric virus71 (EV71) hexanolactam aldehyde compound and its production and use - Google Patents
Anti-enteric virus71 (EV71) hexanolactam aldehyde compound and its production and use Download PDFInfo
- Publication number
- CN103130710B CN103130710B CN201110384897.9A CN201110384897A CN103130710B CN 103130710 B CN103130710 B CN 103130710B CN 201110384897 A CN201110384897 A CN 201110384897A CN 103130710 B CN103130710 B CN 103130710B
- Authority
- CN
- China
- Prior art keywords
- inhibitor
- compound
- pharmaceutical composition
- acid
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
A kind of hexanolactam aldehydes enteric virus71 (Ev71) HRV 3CP inhibitor, its general structure is for shown in chemical combination A, and each variable in structure defines in the description, and these compounds effectively suppress or blocked copying of enteric virus71.The present invention relates to the compound containing formula (A) structure, its various optical isomer, the metabolite of pharmaceutical activity, pharmacologically acceptable salt, solvate and prodrug to catch the discovery of antiviral and application at preparation treatment hand foot mouth disease poison.The invention still further relates to intermediate and the synthetic method of preparation formula (A) structural compounds.
Description
Technical field
The invention relates to formula (A) compound, pharmaceutical composition that treatment enteric virus71 (EV71) is infected, and the synthetic method of this compounds, formulation method and the compound in synthesizing for these.Particularly, the invention provides a class hexanolactam aldehyde compound, the method that the pharmaceutical composition containing this compounds and this compounds for treating EV71 infect.
Background of invention
Hand foot mouth disease (Hand-Foot-Mouthdiscasc, HFMD) has another name called eruptive blister stomatitis, and be the common transmittable disease caused by enterovirus, all there is this sick popular report in world's most countries and area.This disease is propagated mainly through fecal-oral route and respiratory tract, and infectivity by force, very easily causes popular or breaks out.Hand foot mouth disease is based on infant's morbidity, Most patients symptom is slight, clinical manifestation with the fash at heating and the position such as hand, foot, oral cavity for main clinical characteristics, more seriously, virus can also be invaded patient breathing system, central nervous system etc. and cause the symptoms such as encephalitis, pulmonary edema, flaccid paralysis, myocarditis, disease progression is fast, easily death occurs.South East Asia and China are all the hotspots of people's hand foot mouth disease all the time, particularly in the last few years, along with the joint effect of the many factors such as flow of personnel, virus variation, this disease there occurs great outburst in provinces such as China Shandong, Henan, Taiwan, cause the Infant and child deaths case of thousands of example, bring huge economy and moral damage to infant family.
The enterovirus causing hand foot mouth disease has kind more than 20,16,4,5,9,10 types of enterovirus 7I type and CA group, 2,5 types of B group are the more common virus of hand foot mouth disease, and wherein modal is enterovirns type 71 (EV71) and coxsackie virus A 16-type (CoxA16).Virusology and EPDML research confirm, human enterovirus 71 (Enterovirus71, EV71) be the main pathogens of the people's hand foot mouth disease broken out in recent years, the multiple diseases relevant to neural system such as the paralysis (polionyehtishkeparalysis) of aseptic meningitis (ascpticmeningitis), BBE (brainstemencephalitis) and poliomyelitis sample can also be caused simultaneously.EV71 has caused repeatedly popular in recent years, and research finds that the genotype of EV71 constantly changes in the air, and the transgenation in some site causes the pathogenic change of EV71, and therefore the control of EV71 is faced with sizable pressure.Not yet lock bright EV71 virus forms viral persistence and causes the concrete mechanism of hand foot mouth disease at present, still lack special, effective medicine clinically, Chinese medicine or other antiviral drugs can only be taked to treat, research shows, considerable participant does not produce favourable effect to this treatment, constantly occurs death clinically.Therefore, development is needed to have the specific anti-EV71 virus formulation for hand foot mouth disease efficiently.
EV71 is that the people such as Schmit in 1969 are separated first and obtain from the infant faeces sample suffering from central nervous system disease, belongs to Picornaviridae enterovirus and belongs to, and virion be typical body structure above positive two.Its gene is about made up of 7408 Nucleotide, belong to single strand plus RNA virus, only containing an opening code-reading frame (open-readingframe, ORF), the polyprotein (polyprotein) of coding 2194 Amino acid profiles, is respectively the 5 ' non-coding region (UTR) of 746bp and the 3 ' non-coding region of 83bp in genome both sides.The polyprotein (polyprotein) of EV71 genome encoding is about containing 2193 amino acid.In infected cell, this polyprotein is hydrolyzed into as P1, P2, P3 tri-precursor proteins.Proteolytic enzyme through cell and virus is further sheared, and P1 precursor protein can maturation be VP1, VP2, VP3 and VP4 tetra-virus structural proteins further, is responsible for the assembling of virion and stablizes; P2 precursor protein then further maturation is Nonstructural Protein (non-structuralprotcm, nsp) 2A (specific protease), 2B and 2C; P3 precursor protein is then in order to form nonstructural protein 3A, 3B (VPg, 5 ' terminal binding protein), 3C (specific protease) and 3D (RNA-depcndcntRNApolymcrase, RdRp).
In seven Nonstructural Proteins, HRV 3CP is considered to the function mainly exercising specific protease, belong to L-Cysteine HCL Anhydrous, its active centre is the catalytic triads of Cys147, His40, Glu71 composition, be responsible for specifically each protein coded by virus being cut down from poly, form the protein with standalone feature, thus once the afunction of this albumen, then virus is further transcribed and is copied and cannot normally proceed.Therefore the effect of HRV 3CP can be suppressed to be the effective means for the treatment of EV71 virus infection by the selectivity small molecules of specific recognition, HRV 3CP becomes the important drugs target spot for the treatment of hand foot mouth disease.
The present invention is based on the crystal structure characteristic of EV713C proteolytic enzyme, by the binding site in binding activities region, design a series of HRV 3CP inhibitor containing hexanolactam aldehyde structure.
First advantage of the present invention is the hexanolactam aldehydes inhibitor that it provides, and can effectively suppress EV713C proteolytic enzyme.
The hexanolactam aldehydes inhibitor that second advantage of the present invention is to provide, effectively can suppress SARS virus main albumen Nsp5 proteolytic enzyme.
In addition, the 3rd advantage of the present invention may be used for preparation treatment L-Cysteine HCL Anhydrous to induce an illness medicine, as hand foot mouth disease, common cold, poliomyelitis etc.
Find Compound I by biological activity test, the EV71 virus in the cultivation of multiple compound on intracellular such as II, XIV shows extraordinary inhibit activities, has good pharmacokinetic property in vivo.
Target of the present invention is the effective especially micromolecular compound of the anti-enteric virus71 of discovery one class, and is provided for the intermediate of described protease inhibitor compound synthesis and the synthetic method of these synthesis.
Summary of the invention:
The present invention is directed to the deficiencies in the prior art of EV71 virus HRV 3CP inhibitor, there is provided a kind of containing formula (A) class EV71 virus HRV 3CP inhibitor, another object of the present invention to provide the synthesis of described protease inhibitor compound intermediate and the synthetic method for these synthesis.
The present invention relates to the hexanolactam aldehyde compound of formula (A) and/or pharmacy acceptable salt and/or hydrate preparation treatment enteric virus71 (EV71) to catch the application of medicine.These compounds are as its pharmacy acceptable salt and/or hydrate, or as pharmaceutical composition composition (no matter its whether with the antiviral agent of other treatment hand foot mouth disease, anti-infective, immunomodulator or microbiotic administration simultaneously) and for suppressing the HRV 3CP of EV71 virus, or the one or more EV71 viral infection symptoms of preventing/treating.
In particular, the present invention relates to formula (A) compound and/or pharmacy acceptable salt and/or hydrate preparation treatment enteric virus71 (EV71) to catch the application of medicine:
Wherein
R
1expression-H, C1-12 alkyl, C2-12 thiazolinyl, C2-12 alkynyl, C3-8 cycloalkyl, aryl, heteroaryl, aryl C1-8 alkyl, heteroaryl C1-9 alkyl, aryl C2-6 thiazolinyl, heteroaryl C2-6 thiazolinyl, aryl C2-6 alkynyl, heteroaryl C2-6 alkynes its,-O-alkyl,-O-cycloalkyl,-O-mixes alkyl,-O-Heterocyclylalkyl,-O-heterocyclic radical,-O-alkenyl,-O-cycloalkenyl group,-O-mixes thiazolinyl,-O-heterocycloalkenyl,-O-alkynyl group,-O-cycloalkynyl radical,-O-mixes alkynyl,-O-ring is mixed alkynyl,-O-aryl,-O-aralkyl,-O-heteroaryl,-O-heteroaralkyl,-S-alkyl,-S-cycloalkyl,-S-mixes alkyl,-S-Heterocyclylalkyl,-S-heterocyclic radical,-S-alkenyl,-S-cycloalkenyl group,-S-mixes thiazolinyl,-S-heterocycloalkenyl,-S-alkynyl group,-S-cycloalkynyl radical,-S-mixes alkynyl,-S-ring is mixed alkynyl,-S-aryl,-S-aralkyl,-S-heteroaryl,-S-heteroaralkyl,-N-alkyl,-N-cycloalkyl,-N-mixes alkyl,-N-Heterocyclylalkyl,-N-heterocyclic radical,-N-alkenyl,-N-cycloalkenyl group,-N-mixes thiazolinyl,-N-heterocycloalkenyl,-N-alkynyl group,-N-cycloalkynyl radical,-N-mixes alkynyl,-N-ring is mixed alkynyl,-N-aryl,-N-aralkyl,-N-heteroaryl,-N-heteroaralkyl, or optionally can replace by 1 to 4 substituting groups, described 1 to 4 substituting groups are selected from halogen ,-OH ,-SH ,-NO
2,-CN, halogen C1-8 alkyl, C1-8 alkoxyl group, C1-6 alkyl-carbonyl, C1-6 alkylthio, C1-8 carbalkoxy ,-CF
3,
R
2represent alkyl, cycloalkyl, assorted alkyl, Heterocyclylalkyl, heterocyclic radical, alkenyl, cycloalkenyl group, assorted thiazolinyl, heterocycloalkenyl, alkynyl group, cycloalkynyl radical, assorted alkynyl, ring is mixed alkynyl, aryl, heteroaryl, aryl C1-8 alkyl, heteroaryl C1-9 alkyl, aryl C2-6 thiazolinyl, heteroaryl C2-6 thiazolinyl, aryl C2-6 alkynyl, heteroaryl C2-6 alkynyl.The above aryl is phenyl or naphthyl, heteroaryl be connected by ring carbon atom or nitrogen-atoms there is 1,2 or 3 be selected from N, O, heteroatomic five yuan or the hexa-atomic aromatic ring of S, and heterocyclic radical be connected by ring carbon atom or nitrogen-atoms have 1,2,3 or 4 are selected from N, the heteroatomic saturated or undersaturated nonaro-maticity ring of O, S, wherein aryl, heteroaryl, heterocyclic radical, cycloalkyl, alkyl, cycloalkyloxy, alkoxyl group optionally can replace by 1 to 4 substituting groups, described 1 to 4 substituting groups are selected from halogen ,-OH,-SH ,-NO
2,-CN, phenyl, halogen C1-8 alkyl, C1-8 alkoxyl group, C1-6 alkyl-carbonyl, C1-6 alkylthio, C1-8 carbalkoxy ,-CF
3.The above cycloalkyl, cycloalkyloxy, aryl, assorted virtue or heterocyclic radical on two adjacent substituents optionally become 0-3 the heteroatomic 3-6 ring containing O, N, S together.
The above aryl is phenyl or naphthyl, heteroaryl be connected by ring carbon atom or nitrogen-atoms there is 1,2 or 3 be selected from N, O, heteroatomic five yuan or the hexa-atomic aromatic ring of S, and heterocyclic radical be connected by ring carbon atom or nitrogen-atoms have 1,2,3 or 4 are selected from N, the heteroatomic saturated or undersaturated nonaro-maticity ring of O, S, wherein aryl, heteroaryl, heterocyclic radical, cycloalkyl, alkyl, cycloalkyloxy, alkoxyl group optionally can replace by 1 to 4 substituting groups, described 1 to 4 substituting groups are selected from halogen ,-OH,-SH ,-NO
2,-CN, halogen C1-8 alkyl, C1-8 alkoxyl group, C1-6 alkyl-carbonyl, C1-6 alkylthio, C1-8 carbalkoxy, trifluoromethyl.The above cycloalkyl, cycloalkyloxy, aryl, the two-phase adjacent substituents on heteroaryl or heterocyclic radical optionally forms 0-3 the heteroatomic three-six-ring containing O, N, S together.
The pharmaceutical composition comprised in the scope of the invention, comprises formula (A) compound or the upper acceptable salt of its treatment of anti-EV71 anti-viral effective amount, and is mixed with pharmaceutically acceptable pharmaceutical carrier or auxiliary agent.
An importance of the present invention, relate in Mammals, by giving the formula A compound of the content of effective anti-EV71 virus to this Mammals, or its acceptable salt or ester in treatment, or above-mentioned composition, to catch the method for medicine to treat enteric virus71 (EV71).
Another importance of the present invention, relates to formula (A) compound facing upward EV71 virus processed by making virus be exposed to, or its acceptable salt or ester in treatment, under composition described above, finds the active drug for the treatment of hand foot mouth disease.
The pharmaceutical composition that other aspect relates to, can comprise other anti-EV71 preparations in addition, also can comprise the inhibitor of other targets of EV71 virus, as 3D proteinase inhibitor and VP1 protein inhibitor.
The detailed description of preferred embodiment
Definition:
When for herein, unless mentioned separately, be all suitable for following definition:
When addressing each example, (R) or (S), for indicating the absolute configuration of asymmetric center, this indicates is explanation for whole compound instead of independent substituent explanation.
" P1; P2; P3 " used herein identifies, mean from the C-end of peptide analogs, and towards the position of amino acid whose residue that N-end extends, i.e. first position starting from C end of P1 representative, P2 is that second position from C holds is (see BergerA. & SchechtcrI, TransactionsoftheRoyalSocietyLondonsericsB257,249-264 (1970)).
" halogen " used herein one word refer to halogenic substituent, be namely selected from iodine, bromine, chlorine or fluorine.
" C1-6 alkyl " used herein word, no matter when being used alone or combinationally using with another substituting group, refer to the straight or branched alkyl substituent of acyclic, it comprises 1 to 6 carbon atoms, comprise such as methyl, ethyl, propyl group, butyl, hexyl, 1-methylethyl, 1,1-dimethyl ethyl, 1-methyl-propyl and 2-methyl-propyl.
" C3-8 cycloalkyl " used herein word, when no matter being used alone or combinationally using with another substituting group, refers to the straight or branched alkyl substituent of acyclic, it comprises 3 to 8 carbon atoms, comprises such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, suberyl and ring octyl group.
" C1-8 alkoxyl group " used herein word, no matter when being used alone or combinationally using with another substituting group, refer to the straight or branched alkoxy substituent of acyclic, it comprises 1 to 8 carbon atoms, comprise such as methoxyl group, oxyethyl group, propoxy-, butoxy, hexyloxy, 1-methyl ethoxy, 2,2-dimethyl butoxy, 1-methyl hexyloxy and heptan oxygen base.
" C1-8 alkylhalide group " used herein word, when being used alone or combinationally using with another substituting group, refer to acyclic, straight or branched alkyl substituent, it comprises 1 to 8 carbon atoms, has one or morely to be selected from fluorine, chlorine, the hydrogen that bromine or iodine replaces.
" C1-6 sulfenyl " used herein word, when being used alone or combinationally using with another substituting group, refer to acyclic, straight or branched alkyl substituent, containing thiol group, such as thiopropyl.
" unsaturated non-aromatic ring " used herein word, means undersaturated cycloalkyl, such as substituting group cyclohexenyl.
" C3-8 cycloalkyloxy " used herein word, no matter when being used alone or combinationally using with another substituting group, mean-the O-C that substituting group comprises 3 to 8 carbon atoms
3-8cycloalkyl, comprises such as-O-cyclopropyl ,-O-cyclobutyl ,-O-cyclopentyl etc.
" C1-6 alkyl-carbonyl " used herein word, when being used alone or combinationally using with another substituting group, refers to the C1-6 alkyl connected by carbonyl, i.e.-C (O)-C
1-6alkyl.
" aryl " used herein word, means the aromatic monocyclic system containing 6 carbon atoms, or the aromatic bicyclic system containing 10 atoms, such as phenyl and naphthyl-loop systems.
" heteroaryl " used herein word, when being used alone or combinationally using with another substituting group, what mean to be connected by ring carbon atom or nitrogen-atoms has 1,2 or 3 are selected from N, O, S heteroatomic five yuan, hexa-atomic or seven yuan of undersaturated heterocycles, remove hydrogen and derivative monovalent substituent.Suitable ring examples is as thiophene, furans, pyrroles, imidazoles, pyrazoles, thiazole ， oxazole ， isoxazole, 1,2,3-triazoles, 1,2-thiadiazoles, pyridine, pyrazine, pyrimidine, 1,2,4-triazine, benzoxazole, benzothiazole, quinoline.
" low-carbon alkyl, low-carbon (LC) thiazolinyl, low-carbon (LC) alkynyl " used herein word, when being used alone or combinationally using with another substituting group, refer to comprise the acyclic of 1 to 6 carbon atoms, straight or branched alkyl, alkenyl or alkynyl substituting group.
" the acceptable ester of pharmacy " used herein word, when being used alone or combinationally using with another substituting group, mean the ester of Formula (I), wherein any carboxyl-functional base of this molecule or hydroxyl-functional base, preferably carboxyl or hydroxy terminal, replaced by carbalkoxy functional group or ester bond:
Wherein R, R ' part is selected from low-carbon alkyl (as methyl, ethyl, propyl group, butyl, hexyl); Alkoxyalkyl (as methoxyethyl); Alkoxy acyl (as acetoxy-methyl); Aralkyl (as benzyl); Aryloxyalkyl group (as benzene oxygen ethyl); Aryl (as phenyl).Can optionally by halogen, C1-4 alkyl or C1-4 alkoxyl group replace.Other suitable prodrug esters, are listed in herein with for referencial use.This kind of pharmaceutically acceptable ester, usually in mammalian body, is hydrolyzed the sour form being converted into Formula (A).
About above-mentioned ester class, unless otherwise specified, the moieties of any existence is all advantageously containing 1 to 6 carbon atom.Any aryl moiety be present in this ester class, all advantageously comprises phenyl group.
" pharmaceutically acceptable salt " word refers to the salt of formula (A) compound herein, and it is in normal therapeutic treatment, and be applicable to the contact tissue of people and animal and nontoxicity, nonirritant, without anaphylaxis etc.Generally water-soluble or oil soluble, or easily disperse, and be effective on it uses.This word comprises pharmaceutically acceptable acid salt and pharmaceutically acceptable base addition salt.
" pharmaceutically acceptable acid salt " word refers to the character keeping biological activity and free state alkali, and be abiotic upper or other aspects are unwanted, itself and mineral acid are as sulfuric acid, nitric acid, phosphoric acid, hydrochloric acid, Hydrogen bromide, thionamic acid etc., and organic acid is as acetic acid, trifluoracetic acid, Tricholroacetic Acid, styracin, citric acid, toxilic acid, hexanodioic acid, alginic acid, xitix, aspartic acid, phenylformic acid, the horizontal acid of benzene, oxyacetic acid, oxysuccinic acid, lactic acid, propanedioic acid, oxalic acid, nicotinic acid, succinic acid, Whitfield's ointment, stearic acid, tartrate, aniline sulfonic acid over the ground, tri-methyl p-toluenesulfonate, p-methyl benzenesulfonic acid, amygdalic acid, pectinic acid, picric acid, the salt that propionic acid etc. are formed.
" pharmaceutically acceptable base addition salt " word refers to the character keeping biological activity and free state acid, and is abiotic upper or other aspects are unwanted, its be with mineral alkali as ammonia or ammonium or metallicity ion as, sodium, magnesium, copper, zinc, calcium, potassium, the salt that the oxyhydroxide of aluminium etc. or carbonate are formed, particularly preferably be ammonium, potassium, sodium, calcium, magnesium salts.The salt derivative by pharmaceutically acceptable organic atoxic alkali comprises primary amine, secondary amine and tertiary amine, quaternary ammonium compound, the amine be substituted, comprise natural being substituted and amine, cyclammonium and basic ion-exchange resins, as methylamine, dimethyl amine, Trimethylamine, ethylamine, diethylamide, triethylamine, tripropylamine, isopropylamine, tributylamine, thanomin, diethanolamine, dicyclohexylamine, Methionin, arginine, Histidine, caffeine, choline, trimethyl-glycine, ethylene diamine, glycosamine, methylglucosamine, Theobromine, piperazine, piperidines, purine, tetramethyl-ammonium compound, tetraethyl ammonium compound, pyridine, N, N xylidine, N-methyl piperidine, N-methylmorpholine, N, the salt that N-dibenzyl phenylethylamine etc. is formed.Particularly preferred organic non-malicious alkali is isopropylamine, diethylamide, thanomin, Trimethylamine, dicyclohexylamine, choline, caffeine.
Preferred scheme
Preferred version of the present invention comprises formula (A) compound, and wherein hexanolactam part is selected from two different isomer, has the configuration that (i) and (ii) represents:
The hexanolactam of the R configuration wherein preferably represented with structure (ii).
R
1: preferred version of the present invention comprises formula (A) compound, wherein R
1preferably C3-8 cycloalkyl, aryl C1-6 alkyl, heteroaryl C1-9 alkyl, aryl C2-6 thiazolinyl, heteroaryl C2-6 thiazolinyl, aryl C2-6 alkynyl, heteroaryl C2-6 alkynyl, or optionally replace by 1 to 4 substituting groups, described 1 to 4 substituting groups are preferentially selected from halogen ,-OH ,-SH ,-NO
2,-CN, halogen C1-8 alkyl, C1-8 alkoxyl group.
Most preferred R
1for the styroyl be optionally substituted by halogen.
R
2: preferred version of the present invention comprises formula (A) compound, wherein R
2preferably aryl C2-6 thiazolinyl, heteroaryl C2-6 thiazolinyl, aryl C1-6 alkyl, heteroaryl C1-9 alkyl, C3-8 cycloalkyl, aryl C2-6 alkynyl, heteroaryl C2-6 alkynyl, or optionally replace by 1 to 4 substituting groups, described 1 to 4 substituting groups are first selected from halogen,-OH ,-SH, C1-8 alkoxyl group.
Most preferred R
2for aryl C2-6 thiazolinyl, heteroaryl C2-6 thiazolinyl.
Hexanolactam compounds of the present invention can exist in a free form or in the form of salts.Pharmacy acceptable salt of the known chemical compound lot type of those skilled in the art and preparation method thereof.Pharmacy acceptable salt comprises conventional avirulent salt, comprises the quaternary ammonium salt that such compound alkali and inorganic or organic acid are formed.
Compound of the present invention can form hydrate or solvate.The hydrate that those skilled in the art are known to be formed compound during freeze-drying together with water or form the method for solvate when concentrating with suitable organic solvent in the solution.
The present invention comprises the medicine containing therapeutic dose the compounds of this invention, and the pharmaceutical composition of one or more pharmaceutically acceptable carriers and/or vehicle.Carrier comprises as salt solution, buffer saline, glucose, water, glycerine, ethanol and their binding substances.Carrier or vehicle can also comprise time lag material known in the art, as glyceryl monostearate or distearin, also can comprise wax, ethyl cellulose, Vltra tears, methyl methacrylate etc.If needed, said composition can also comprise wetting agent or the emulsifying agent of comparatively a small amount of, or pH buffer reagent.Said composition can be liquid, suspension, emulsion, tablet, pill, capsule, extended release preparation or powder.Said composition can be mixed with suppository with traditional tamanori and carrier such as triglyceride.Oral preparations can comprise the mannitol of standard vector as medicine grade, lactose, starch, Magnesium Stearate, soluble saccharin, Mierocrystalline cellulose and magnesiumcarbonate etc.Optionally preparation and determining, preparation can design mixing, granulates and compression or solvent components.In another approach, said composition can be mixed with nano particle.
Pharmaceutical composition of the present invention can with medicament forms administration miscellaneous.The pharmaceutical carrier used can be solid or liquid.
If use solid carrier, preparation can be tablet, is placed into powder in hard capsule or piller form or lozenge or Lozenge forms.The amount of solid carrier changes to a great extent, but preferably from about 25mg to about 10g.Typical solid carrier comprises lactose, terra alba, sucrose, talcum, gel, agar, pectin, gum arabic, Magnesium Stearate, stearic acid etc.Solid carrier can comprise one or more may make sweetener, lubricant, solubilizing agent, suspension agent, filler, glidant, compression aid simultaneously, the material of tackiness agent or tablet-disintegrating agents; It can also be encapsulating material.In the powder, carrier is pulverizing solid, and it mixes with pulverizing activeconstituents.Activeconstituents mixes with suitable ratio with the carrier with necessary compression property in tablets, with the shape needed and size compression.Powder and tablet preferably comprise 99% activeconstituents at the most.
If use liquid vehicle, preparation can be syrup, emulsion, soft capsule, the aseptic injectable solution in the liquid suspension of ampoule or bottle or non-water or suspension.Typical liquid vehicle comprises syrup, peanut oil, sweet oil, water, etc.Liquid vehicle for the preparation of solution, suspension, emulsion, syrup, the composition of tincture and sealing.Activeconstituents can dissolve or be suspended in pharmaceutically acceptable liquid vehicle as water, organic solvent, the mixture of the two or pharmaceutically acceptable oils or fat.Liquid vehicle can comprise other suitable medicated premixs as solubilizing agent, emulsifying agent, buffer reagent, sanitas, sweetener, sweetener, suspension agent, thickening material, pigment, viscosity modifier, stable formation osmo-regulators.Suitable example for the liquid vehicle of oral and administered parenterally comprises water and (partly comprises as above-mentioned additive, such as derivatived cellulose, preferably carboxymethyl cellulose sodium salt solution), alcohol (comprises monohydroxy-alcohol and polyvalent alcohol, such as ethylene glycol) and their derivative, and oils (such as fractionated coconut oil and peanut oil).Carrier for administered parenterally can also be that grease is as ethyl oleate and isopropyl myristate.Aseptic liquid vehicle is used for the aseptic fluid composition of administered parenterally.Liquid vehicle for pressurized compositions can be halohydrocarbon or other pharmaceutically acceptable propelling agents.Sterile solution or aaerosol solution composition of liquid medicine can be used for, such as, and intravenously, intramuscular, intraperitoneal or subcutaneous injection.Can the known technology in field at all, use suitable dispersion agent or wetting agent (as tween 80) and suspension agent to allocate this suspension.Can push or inject perfusion in the passages through which vital energy circulates of 30 minutes gradually by single during injection.This compound can also with the form oral administration of liquid or solids composition.Parenteral word used herein, comprises in subcutaneous, intracutaneous, intramuscular, intravenously, intraarticular, synovial membrane, in breastbone, in sheath and intralesional injection or infusion techn.
In order to obtain stable water miscible formulation, compound or its pharmacy acceptable salt can be dissolved in organic or inorganic aqueous acid, 0.3M succsinic acid or citric acid solution.Optionally, acid derivative can be dissolved in suitable basic solution.If can not get soluble form, compound can be dissolved in suitable cosolvent or their combination.The example of its suitable solvent like this includes but are not limited to, concentration range from the ethanol of 0-60% cumulative volume, propylene glycol, Liquid Macrogol, polysorbate 80, glycerine, polyoxyethylene fatty acid ester, fatty alcohol or glycerine hydroxy fatty acid ester etc.
Pharmaceutical composition of the present invention can oral, parenteral or the holder administration by implanting, oral administration or by preferred during drug administration by injection.Various release system is known and may be used for the administration of compound or other various preparations, and these preparations comprise tablet, capsule, injectable solution, the capsule in liposome, particulate, microcapsule, etc.The method introduced includes, but are not limited to skin, intracutaneous, and intramuscular is endoperitoneal, intravenous, subcutaneous, nasal cavity, lung, peridural, eyes and (usually preferred) oral route.Compound can pass through easily any or other suitable administration, such as by injecting or bolus injection, by epithelium or mucous membrane circuit (such as, oral mucosa, rectum and intestinal mucosa, etc.) to absorb or by the support of carrying medicament and can in other biological promoting agent together administration.Can whole body or topical.For nose, when the treatment of segmental bronchus or lung disease or prevention, preferred route of administration is oral, nasal administration or segmental bronchus smoke substance or atomizer.
For other suitable vehicle of composite mentioned above and composition or carrier, can find in Standard pharmacological textbook, such as, at " Remington ' sPharmaccuticalSciences ", in the 19th edition.In order to the hand foot mouth disease that prevention and therapy EV71 virus causes, in single therapy, HRV 3CP inhibitor compound described in this article, the dosage range between about 0.01 to about 100mg/kg body weight every day is useful, preferably 0.5 arrives between 75mg/kg body weight every day.Usually, pharmaceutical composition of the present invention is by administration every day about 1 to 5 times, or an other continuous print transfusion.This kind of medicine can be used as chronic or acute treatment.Can mix with carrier substance, produce the content of the activeconstituents of single dose form, can change according to the AD HOC of pending host and administration.Representational preparation will containing 5% to about 95% activeconstituents (w/w) of having an appointment.Preferably, this kind of preparation containing have an appointment 20% to about 80% active compound.
Understanding may need than higher or lower dosage mentioned above by this to be familiar with this area.Should determine according to various factors the given dose of particular patient and processing mode, comprise the activity of used specific compound, the combination of time of age of patient, body weight, sex, general state of health, diet, administration, metabolic rate, medicine, and infect seriousness and process, patient to infect tendency, also have process doctor judgement.Generally speaking, with in fact lower than the low dose of begin treatment of the optimal dose of this compound.Dosage is increased subsequently, until reach best effect in this case by a small amount of increase.Generally speaking, require with normally to produce effective antiviral result, but do not cause the levels of any harmful or disadvantageous side effect to cast this compound.
When composition of the present invention comprise formula (A) compound and one or more other treatments or preventive combine time, the amount of this compound and other preparation should provide with the dosage level between about 10 to 100%, the more preferably dosage of about 10 to 80%, gives with single therapy method usually.
When these compounds or its pharmaceutically acceptable salt is allocated together with pharmaceutically acceptable carrier time, give Mammals in vivo by the composition of gained, as the mankind, so that treatment or prevention EV71 virus infection.Also the compounds of this invention can be used to mix with lower series preparation, carried out this kind for the treatment of, including, but not limited to: immunomodulator, as α, β, δ-Interferon, rabbit; Other anti-virus formulation, as acyclovir, ganciclovir; Other EV713C proteinase inhibitor; To the inhibitor of other targets in EV71 Life Cycles, as 3D proteolytic enzyme, VP1 albumen; Or its composition.Other preparation can be mixed with the compounds of this invention, to produce single dosage form.In addition, also this kind of other preparation can be cast Mammals respectively, become a part for multiple dosage form.Therefore, other concrete scheme of the present invention provides a kind of in Mammals, and by giving construction (M) compound, wherein substituting group is as defined above, suppresses the method for EV71 virus.
In preferred concrete scheme, these methods have for reducing EV71 replication in Mammals.If pharmaceutical composition only comprises the compounds of this invention as activeconstituents, these class methods can comprise in addition and are selected from immunomodulator to this Mammals, antiviral agent, other EV71 virus HRV 3CP inhibitor, or to other targets in EV71 Life Cycles, as 3D proteinase inhibitor and VP1 protein inhibitor.Can before giving the present composition, simultaneously or afterwards, give Mammals by this kind of other preparation.
Technical process
Formula (A) compound can be prepared effectively by the inventive method, comprises and adopts following general synthetic method.R in these synthetic methods
1, R
2definition as above.
Technical process I:
Intermediate 1-4 obtains through the route synthesis of flow process I; in this flow process; with L-glutamic acid 1-1 for raw material; first carboxyl is carried out esterification protection; subsequently its amino is carried out protective group and obtain its intermediate 1-2; then with using LiHMDS (or other strong basic reagents) by compound 1-2 deprotonation, introducing cyanoethyl group and obtaining intermediate 1-3.Then by the cyano reduction of intermediate 1-3, and then intramolecular amideization reaction occurs, in molecule, Cheng Huan obtains key intermediate 1-4.
The preparation of step I-1 compound N-Boc-glutamic acid dimethyl ester (1-2)
Under 0 DEG C of condition, Acetyl Chloride 98Min. (5.0mL) is slowly added dropwise in methyl alcohol (100.0mL), stirs 5 minutes, then L-glutamic acid (10.0g is added, 67.9mmol), continue to stir and be heated to backflow, keeping reflux temperature to react 2 hours.Stopped reaction, underpressure distillation is except desolventizing.The oily matter obtained is dissolved in THF, TFA (28.54mL is dripped under 0 DEG C of condition, 203.7mmol), 0 DEG C is kept to stir 5 minutes, continuation dropping is dissolved in the tert-Butyl dicarbonate (17.78g in THF (30.0mL), 81.5mmol), room temperature reaction is stirred to 2.5 hours.After reaction terminates, removal of solvent under reduced pressure, after residue use water (200.0mL) dissolves, adding citric acid acidify solution, to PH=4, adds DCM (2 × 100.0mL) extraction, merge organic phase, organic phase organic phase anhydrous sodium sulfate drying after saturated common salt water washing, then concentrates, and the crude product obtained is through flash chromatography post (PE: EA=5: 1) purifying, obtain target compound (1-2) (17.8g, productive rate 95.2%).The preparation of step 1-2 compound 2-t-butoxycarbonyl amino-4-cyanoethyl-Methyl glutarate (1-3)
By two (trimethyl silicon based) Lithamide (THF solution of 78.5mL1.0M, 78.5mmol) be added to N-Boc-glutamic acid dimethyl ester (the 1-2) (10.0g of-78 DEG C, in anhydrous THF (200.0mL) solution 36.4mmol), and gained solution is stirred 30 minutes in this temperature.Then slowly drip bromopropionitrile (3.4mL), reaction mixture is continued stirring 2 hours at-78 DEG C.After question response terminates, add Glacial acetic acid (5.0mL) cancellation reaction, be stirred to room temperature.Removal of solvent under reduced pressure, after residue use water (100.0mL) dissolves, with DCM extraction (100.0mL × 3), merge organic phase, use saturated common salt water washing, and by organic phase anhydrous sodium sulfate drying, then concentrate, the thick thing obtained, through flash chromatography post (E: EA=2: 1) purifying, obtains target compound (1-3) (7.1g, productive rate 59.5%).
The preparation of step 1-3 compound 2-t-butoxycarbonyl amino-3-(2-carbonyl-3-piperidines alkane)-methyl propionate (1-4)
At 2-t-butoxycarbonyl amino-4-cyanoethyl-Methyl glutarate (1-4) (5.0g, cobalt chloride hydrate (4.0g is added in methyl alcohol (80.0mL) solution 15.9mmol), 15.9mmol), then under 0 DEG C of condition, sodium borohydride (6.0g is added to gradation in obtained pink solution, 159.5mmol), stirring at room temperature 18 hours.TLC monitors reaction, after question response, adds saturated aqueous ammonium chloride (30.0mL) cancellation reaction, stirs 10 minutes.Suction filtration removing solid impurity, decompression removing easy volatile solvent, residual liquid is with after DCM (100.0mL × 3) extraction, and add water (2 × 50.0mL) washs organic phase.The organic phase saturated sodium-chloride water solution merged washs, anhydrous sodium sulfate drying, filter steaming and desolventize, the crude product obtained is through flash chromatography post (EA) purifying, finally obtain key intermediate (1-4) (2.9g, productive rate 60.7%).
Flow process II
Structural unit 2-4 is obtained by flow process II synthesis, wherein R
1, R
2its group represented describes above.With compound 2-1 for raw material, first carry out carboxyl esterization protection and obtain compound 2-2, then carry out condensation from different organic acid 2-3 and obtain intermediate 2-4.
Flow process III
Formula (A) compound in the present invention sloughs carbonyl-protection base by compound 1-4 deaminize protecting group and compound 2-4 to carry out condensation, then carry out derivatize further and obtain compound 3-1.
Flow process IV
This flow process is the structure derivatize carrying out compound 3-1, has obtained hexanamide aldehyde formula (A) compound.Wherein, formula of the present invention (A) compound can be obtained by compound 3-1 derivatize through following synthetic route.
Step IV-1 compound 2-[2-R
2-amino-1-carbonyl-3-R
1] preparation of the third amino-3-(2-carbonyl-3-piperidines alkane)-propyl alcohol (4-1)
To 2-[2-R
1-amino-1-carbonyl-3-R
3] the third amino-3-(2-carbonyl-3-piperidines alkane)-methyl propionate (1.0equiv.) methanol solution (10.0mL) in gradation add sodium borohydride (10.0equiv.), stirring at room temperature 2 hours.Add saturated aqueous ammonium chloride (5.0mL) cancellation reaction, decompression removing methyl alcohol.Extract with DCM (3 × 50.0ml), the organic phase saturated nacl aqueous solution merged washs, anhydrous sodium sulfate drying, then concentrate, the crude product obtained, through flash chromatography post (DCM: MeOH=50: 1) purifying, obtains target compound (4-1) (productive rate 87.8%).
Step IV-2 compound 2-[2-R
2-amino-1-carbonyl-3-R
1] preparation of the third amino-3-(2-carbonyl-3-piperidines alkane)-propionic aldehyde (4-2)
To 2-[2-R
4-amino-1-carbonyl-3-R
3] the third amino-3-(2-carbonyl-3-piperidines alkane)-propyl alcohol (1.0equiv.) anhydrous DCM (10.0mL) solution in add DMP (1.0equiv.), stir 2 hours.Add saturated sodium bicarbonate (2.0mL) cancellation reaction, add Sulfothiorine (2.0equiv) simultaneously, be stirred to organic phase clarification.Extract with DCM (3 × 50.0mL), the organic phase anhydrous sodium sulfate drying merged, then concentrate, the crude product obtained, through flash chromatography post (DCM: MeOH=30: 1) purifying, obtains target compound 4-2 (productive rate 81.3%).
Example
By following unrestricted example, illustrate in greater detail the present invention, but the present invention is not limited to following instance.Temperature is provided with degree centigrade in following Examples.Unless stated separately, Solution percentages represents the relation of weight to volume, and solution proportion represents the relation of volume-for-volume.In example, the structure of compound is determined in order to lower one or many clock methods: nuclear magnetic resonance spectrometer, high resolution mass spectrum analysis, thin-layer chromatography.If structural formula and its chemical name of the expression compound provided are not inconsistent, be as the criterion with structural formula.
Nuclear magnetic resonance spectrum (
1hNMR and
13cNMR) measure under 400MHz field intensity with Bruker400 spectrometer.Chemical shift represents with moving down how many 1,000,000/(ppm, δ) relative to interior mark tetramethylsilane standard.
1in H-NMR, the multiplicity at peak is expressed as follows: s=is unimodal; D=doublet; T=triplet; M=multiplet.Coupling constant hertz represents.Solvent peak is with reference to inner deuterated reagent.Commercial reagents used be all respectively from they separately supplier there obtain, if there is the condition that need process, be otherwise noted in literary composition.Tetrahydrofuran (THF) (THF) obtains through sodium-benzophenone system distillation before use; Methylene dichloride (DCM) obtains from hydrolith distillation before use.
Use following abbreviations herein: Me: methyl; MeOH: methyl alcohol; Boc: uncle-butoxy carbonyl; TEA: triethylamine; EtOAc: ethyl acetate; DMP:Dess-martin reagent; PE: sherwood oil; Et
2o: ether; TFA: trifluoroacetic acid; EDC:1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride); HOBt:1-hydroxy benzo triazole hydrate.In addition, " L " represents naturally occurring amino acid.FBS: foetal calf serum; PBS solution: phosphoric acid buffer: PBST: phosphoric acid buffer adds Tween-20; ESMS: Electrospray Ionization Mass Spectrometry; MS: mass spectroscopy; HPLC: high performance liquid chromatography.
The example of embodiment of the present invention is as described below:
The preparation of embodiment 1N-Boc-L-(+)-glutamic acid dimethyl ester (1-2)
Under 0 DEG C of condition, Acetyl Chloride 98Min. (5mL) is slowly added dropwise in methyl alcohol (100mL), stirs 5 minutes, then add L-glutamic acid (10g, 67.9mmol), continue to stir and be heated to backflow, keep reflux temperature to react 2 hours.Stopped reaction, removal of solvent under reduced pressure, uses Diethyl ether recrystallization.The oily matter obtained is dissolved in THF (150mL), TEA (28.5mL is dripped under 0 DEG C of condition, 203.7mmol), 0 DEG C is kept to stir 5 minutes, continuation dropping is dissolved in the tert-Butyl dicarbonate (17.8g in THF (30mL), 81.5mmol), room temperature reaction is stirred to 2.5 hours.After reaction terminates, remove solvent under reduced pressure, water (200mL) is added in residue, extract from aqueous phase with DCM (2 × 200mL), the organic phase anhydrous sodium sulfate drying of merging, then concentrates, the crude product obtained is through flash chromatography post (PE: EA=5: 1) purifying, obtaining N-Boc-L-(+)-glutamic acid dimethyl ester (17.7g, productive rate 95.2%) is colourless oil liquid, TLC: R
f=0.5 (PE: EA=5: 1);
1h-NMR (400MHz, CDCl
3): δ 5.36 (m, 1H), 4.32 (m, 1H), 3.75 (s, 3H), 3.68 (s, 3H), 2.43 (m, 2H), 2.19 (m, 1H), 1.96 (m, 1H), 1.440 (s, 9H);
13c-NMR (100MHz, CDCl
3): δ 173.0,172.6,155.3,79.7,52.7,52.2,51.6,30.0,28.1 (3), 27.5.
The preparation of embodiment 22-t-butoxycarbonyl amino-4-cyanoethyl-Methyl glutarate (1-3)
Under the condition of-78 DEG C, by the THF solution of two (trimethyl silicon based) Lithamide (78.5mL1.0) M, 78.5mmol) be slowly added drop-wise to N-Boc-L-(+)-glutamic acid dimethyl ester (1-2) (10g, in anhydrous THF (200mL) solution 36.4mmol), and gained solution is stirred 30 minutes at this temperature.Then keep temperature-resistant, slowly drip bromopropionitrile (3.4mL), reaction mixture is continued stirring 2 hours under the condition of-78 DEG C.After question response, add Glacial acetic acid (5mL) cancellation reaction, be stirred to room temperature.First decompression is revolved and is desolventized, then water (200mL) is added, by DCM (2 × 200mL) aqueous phase extracted, the organic phase anhydrous sodium sulfate drying merged, then concentrate, the crude product obtained, through flash chromatography post (PE: EA=2: 1) purifying, obtains 2-t-butoxycarbonyl amino-4-cyanoethyl-Methyl glutarate (7.1g, productive rate 59.5%) be pale yellow oily liquid body, TLC: R
f=0.4 (PE: EA=2: 1);
1h-NMR (400MHz, CDCl
3): δ 5.07 (d, J=8.8Hz, 1H), 4.36 (dd, J=12.4Hz, 1H), 3.75 (s, 3H), 3.72 (s, 3H), 2.63 (m, 1H), 2.39 (m, 2H), 1.96-2.06 (m, 4H), 1.45 (s, 9H);
13c-NMR (100MHz, CDCl
3): δ 174.38,172.34,155.37,118.67,80.33,52.56,52.17,51.56,40.78,34.46,28.26,27.32,15.15.
The preparation of embodiment 32-t-butoxycarbonyl amino-3-(2-carbonyl-3-piperidines alkane)-methyl propionate (1-4)
To 2-t-butoxycarbonyl amino-4-cyanoethyl-Methyl glutarate (1-4) (5g, cobalt chloride hydrate (4g is added in methyl alcohol (80mL) solution 15.9mmol), 14.6mmol), then under 0C condition, in obtained pink mixture, sodium borohydride (6g is slowly added several times, 157.9mmol), stirring at room temperature 18 hours.Add saturated aqueous ammonium chloride (30mL) cancellation reaction, stir 10 minutes.Suction filtration removing solid impurity, removes easy volatile solvent under reduced pressure.Extract from aqueous phase with DCM (3 × 100mL), the organic phase anhydrous sodium sulfate drying merged, then concentrate, the crude product obtained is through flash chromatography post (EA) purifying, obtain 2-t-butoxycarbonyl amino-3-(2-carbonyl-3-piperidines alkane)-methyl propionate (2.9g, productive rate 60.7%) be white foam solid, TLC: R
f=0.4 (EA);
1h-NMR (400MHz, CDCl
3): δ 6.007 (s, 1H), 5.60 (d, J=8.4Hz, 1H), 4.32 (m, 1H), 3.73 (s, 3H), 3.2 (t, J=3.2Hz, 2H), 2.32 (m, 1H), 1.60-1.90 (m, 4H), 1.44 (s, 9H);
13c-NMR (100MHz, CDCl
3.): δ 174.54,173.21,155.92,79.74,52.26,51.75,42.29,38.03,34.25,28.29,26.57,21.57.
The preparation of embodiment 4 Chinese cassia tree carbonyl phenylalanine methyl ester (2-4)
To phenylalanine methyl ester (10g under 0 DEG C of condition, in DCM (100mL) solution 55.8mmol), add styracin (9.9g, 67.0mmol) successively, EDC (16.1g, 83.8mmol), HOBt (11.3g, 83.8mmol), then drips TEA (35.2mL, 251.4mmol), room temperature is stirred to 2 hours.Remove solvent under reduced pressure, add water (200mL), extract from aqueous phase with DCM (2 × 200mL), the organic phase anhydrous sodium sulfate drying merged, then concentrate, the crude product obtained, through flash chromatography post (PE: EA2: 1) purifying, obtains Chinese cassia tree carbonylamino-phenylalanine methyl ester (13.8g, productive rate 80.2%) be white solid, TLC: R
f=0.5 (PE: EA2: 1):
1hNMR (400MHz, CDCl
3) δ 7.64-7.60 (d, 1H, J=16Hz), 7.47-7.11 (m, 10H), 6.42-6.38 (d, 1H, J=16Hz), 5.06-5.02 (m, 1H), 3.74 (s, 3H), 3.26-3.14 (m, 2H):
13c-NMR (100MHz, CDCl
3): δ 172.2,165.4,141.8,135.9,134.6,129.8,129.3 (2), 128.8 (2), 128.6 (2), 127.9 (2), 127.2,120.0,53.4,52.4,37.9.
The preparation of embodiment 5 Chinese cassia tree carbonyl phenylalanine (2-5)
Lithium hydroxide (2.0g, 48.5mmol) is added, stirring at room temperature 1.5 hours in the methyl alcohol and water (100mL:200mL) solution of Chinese cassia tree carbonylamino-phenylalanine methyl ester (2-4) (10g, 32.3mmol).Remove solvent under reduced pressure, add 1N hydrochloric acid and pH is adjusted to 3.With ethyl acetate (3 × 100mL) extraction, merge organic phase, with anhydrous sodium sulfate drying, then concentrate, obtaining Chinese cassia tree carbonylamino-phenylalanine (8.6g, productive rate 90.6%) is white solid, TLC:R
f=0.1 (PE: EA=2: 1);
1h-NMR (400MHz, CDCl
3): δ 7.65-7.61 (d, 1H, J=16Hz), 7.35-7.18 (m, 10H), 6.39-6.35 (d, 1H, J=16Hz), 5.02-5.00 (m, 1H), 3.30-3.20 (m, 2H);
13c-NMR (100MHz, CDCl
3): δ 166.4,142.6,135.7,134.4,130.1,129.4 (2), 128.9 (2), 128.6 (2), 128.8 (2), 128.0,127.3,119.4,53.7,53.7,37.2.
The preparation of implementation column 62-[2-(Chinese cassia tree carbonyl)-amino-1-carbonyl-3-phenyl] the third amino-3-(2-carbonyl-3-piperidines alkane)-methyl propionate (3-1)
Under 0 DEG C of condition, drip TFA (13mL) in the anhydrous DCM (80mL) of 2-t-butoxycarbonyl amino-3-(2-carbonyl-3-piperidines alkane)-methyl propionate (5g, 16.6mmol), ice bath stirs 1.5 hours.Remove solvent under reduced pressure, adjust pH to neutral with triethylamine.Then be dissolved in DCM (100mL), Chinese cassia tree carbonylamino-phenylalanine (5.8g is added successively under 0 DEG C of condition, 19.9mmol), EDC (4.7g, 24.9mmol), HOBt (3.4g, 24.9mmol), then drip TEA (10.5mL, 74.7mmol), be stirred to room temperature 2 hours.Wash with water (3 × 50mL), organic phase anhydrous sodium sulfate drying, then concentrate, the crude product obtained is through flash chromatography post (DCM: MeOH=20: 1) purifying, obtain 2-[2-(Chinese cassia tree carbonyl)-amino-1-carbonyl-3-phenyl] the third amino-3-(2-carbonyl-3-piperidines)-methyl propionate (6.9g, 87.8%) be white foam solid, TLC:R
f0.5 (DCM: MeOH=20.1);
1h-NMR (400MHz, CDCl
3): δ 7.49 (d, J=16Hz, 1H), 7.21-7.35 (10H), 6.46 (d, J=16Hz, 1H), 4.87 (q, J=3.2Hz, J=4Hz, 1H), 3.73 (s, 3H), 3.42 (m, 1H), 3.09-3.25 (m, 4H), 2.41 (m, 1H), 223 (m, 1H), 1.30-1.80 (6H);
13c-NMR (100MHz, CDCl
3): δ 172.05,165.26,141.89,135.83,134.63,129.89,128.85,128.63,127.92,127.19,119.96,53.31,52.42,37.91.
The preparation of embodiment 71-cyano group-2-[2-(Chinese cassia tree carbonyl)-amino-1-carbonyl-3-phenyl] the third amino-3-(2-carbonyl-3-piperidines alkane)-propyl alcohol (3-2)
To 2 [2-(Chinese cassia tree carbonyl)-amino-1-carbonyl-3-phenyl] the third amino-3-(2-carbonyl-3-piperidines alkane)-methyl propionate (3-1) (1g, sodium borohydride (0.8g is added several times in methanol solution (10mL) 2.2mmol), 21.6mmol), stirring at room temperature 2 hours.Add saturated aqueous ammonium chloride (5mL) cancellation reaction, remove easy volatile solvent under reduced pressure, extract with DCM (3 × 50mL), the organic phase anhydrous sodium sulfate drying merged, then concentrate, the crude product obtained is through flash chromatography post (DCM: McOH=20: 1) purifying, obtain 2-[2-(Chinese cassia tree carbonyl)-amino-1-carbonyl-3-phenyl] the third amino-3-(2-carbonyl-3-piperidines alkane)-propyl alcohol (0.8g, productive rate 80.9%) consolidate for white foam, TLC:R
f=0.4 (DCM: McOH20: 1);
1h-NMR (400MHz, CDCl
3): δ 7.49 (d, J=16Hz, 1H), 7.21-7.35 (10H), 6.46 (d, J=16Hz, 1H), 4.87 (q, J=3.2Hz, J=4Hz, 1H) .3.71 (m, 2H), 3.42 (m, 1H), 3.09-3.25 (m, 4H), 2.41 (m, 1H), 2.23 (m, 1H) .1.30-1.80 (6H);
13c-NMR (100MHz, CDCl
3): δ 179.89,171.21,166.12,141.64,136.76,134.62,129.87,129.37,128.82,128.50,127.94,126.86,120.28,66.2,54.89,54.81,41.08,39.11,38.96,29.42,28.10,26.72.
The preparation of implementation column 82-[2-(Chinese cassia tree carbonyl)-amino-1-carbonyl-3-phenyl] the third amino-3-(2-carbonyl-3-piperidines alkane)-propionic aldehyde (3-3)
To 2-[2-(Chinese cassia tree carbonyl)-amino-1-carbonyl-3-phenyl] the third amino-3-(2-carbonyl-3-piperidines alkane)-propyl alcohol (3-2) (1g, DMP (1.5g is added in anhydrous DCM (10mL) solution 2.3mmol), 3.4mmol), stir 2 hours.Add saturated sodium bicarbonate (2.0mL) cancellation reaction, add Sulfothiorine (1.1g, 6.9mmol) simultaneously, be stirred to organic phase clarification.Add DCM (3 × 50mL) extraction, the organic phase anhydrous sodium sulfate drying merged, then concentrate, the crude product obtained is through flash chromatography post (DCM: MeOH=30: 1) purifying, obtain 2-[2-(Chinese cassia tree carbonyl)-amino-1-carbonyl-3-phenyl] the third amino-3-(2-carbonyl-3-piperidines alkane)-propionic aldehyde (0.83g, productive rate 80.7%) see for white foam solid, TLC:R
10.5 (DCM: MeOH=20: 1);
1h-NMR (400MHz, CDCl
3): δ 9.40 (s, 1H), 8.41 (d, J=6.4Hz), 7.58 (d, J=16Hz, 1H), 7.23 (10H), 6.49 (d, J=16Hz, 1H), 5.08 (m, 1H), 4.32 (m, 4H), 1.47-2.27 (7H);
13c-NMR (100MHz, CDCl
3): δ 200.20,175.09,172.29,165.80,141.51,136.46,134.72,129.79,129.49,128.81,128.53,127.91,126.97,120.38,57.09,54.38,42.19,38.82,37.18,30.74,27.06,21.1.
Embodiment 9EV713C proteinase inhibitor vitro enzyme is lived and is screened
Utilize FRET (fluorescence resonance energy transfer) (fluorescenceresonanceenergytransfer, FRET) technical measurement is lived for the enzyme of the inhibitor of HRV 3CP, according to HRV 3CP recognition site design substrate: Dabcyl-RTATVQGPSLDFE-Edans, inhibitor ultimate density is respectively: 1mM, 500 μMs, 250 μMs, 125 μMs, 62.5 μMs, 31.25 μMs, 15.625 μMs, 7.8125 μM, 3.9 μM, 1.95 μM, 976nM, 488nM, 244nM, 122nM, 61nM, 30.5nM, 15.3nM, 3.8nM, 1.9nM, 0.95nM, establish negative control simultaneously.Utilize 96 orifice plates to measure enzyme to live, 100 μ l reaction systems comprise: 20mMMESpH6.5,10ug/mlBSA, 10 μMs of EV713C albumen, the inhibitor of 150 μMs of fluorogenic substrates and different concns, 37 DEG C of reactions, by microplate reader fluorescence intensity, the data obtained utilizes software GraphPadPrism5 process to be inhibited the IC of agent
50.Observations shows, Compound II per, the IC of VI
50for 5-50nM.
Embodiment 10SARS main protease Nsp5 inhibitor vitro enzyme is lived and is screened
Before utilizing fluorescence resonance, amount shifts (fluoresccnccresonanceenergytransfer, FRET) technical measurement is lived for the enzyme of the inhibitor of SARSNsp5 proteolytic enzyme, according to Nsp5 protease site design substrate: MCA-AVLQSGFR-L-Dnp, inhibitor ultimate density is respectively 1mM, 500 μMs, 250 μMs, + 125 μMs, 62.5 μMs, 31.25 μMs, 15.625 μMs, 7.8125 μM, 3.9 μM, 1.95 μM, 976nM, 488nM, 244nM, 122nM, 61nM, 30.5nM, 15.3nM, 3.8nM, 1.9nM, 0.95nM, establish negative control simultaneously.Utilize 96 orifice plates to measure enzyme to live, 100 μ l reaction systems comprise: 50mMTris-HClpH7.3,1mMEDTA, 0.5 μM of SARSnsp5 albumen, the inhibitor of 16 μMs of fluorogenic substrates and different concns, 37 DEG C of reactions, by microplate reader fluorescence intensity, the data obtained utilizes software GraphPadPrism5 process to be inhibited the IC of agent
50.Observations shows, Compound I, the IC of VIII
50for 0.1-5 μM.
Embodiment 11 cytopathic effect screening Cytopathiceffect (CPE) assay:
In CPE experiment, cell used is RD (humancmbryonicrhabdomyosarcoma) cell, and (titre is 100TCID in the viral standard virus strain for EV71
50).In 96 orifice plates, every hole adds 100 μ lRD cells (concentration is 3 × 10
4individual/hole), allow after cell attachment 1d, add the inhibitor that 50 μ l/ holes have been diluted, inhibitor final concentration is respectively: 100 μMs, 10 μMs, 5 μMs, 2.5 μMs, 1.25 μMs, 625nM, 312nM, 156nM, 78nM, 39nM, 19.5nM, 9.75nM, 3.9nM.Each concentration 4 holes, in triplicate, add 50 μ l/ hole EV71 viruses, observe cytopathic effect (cytopathiceffect, CPE) after 2-3d after 2h.When observations shows the cell survival of 50%, the inhibition concentration of chemical combination I is 0.625 μM-1.25 μMs.
Embodiment 12 virus replication rejection ability screening Cell-basedimmunodetcction (CID) assay:
In CID experiment, RD (humanembryonicrhabdomyosarcoma) cell is diluted to 3 × 10 with DMEM (Dulbecco ' sModifiedEagle'sMedium) substratum containing 10%FBS phase 1%PS after trysinization
4individual/ml, adds 100 μ l/ hole RD cells, 37 DEG C, 5%CO in 96 orifice plates
2overnight incubation, within second day, add the inhibitor that 50 μ l/ holes have been diluted, final concentration is respectively: 25 μMs, 10 μMs, 5 μMs, 2.5 μMs, 1.5 μMs, 1.3 μMs, 1.1 μMs, 0.9 μM, 0.7 μM, 0.5 μM, 0.166 μM, 0.05 μM.(titre is 100TClD to add 50 μ l/ hole EV71 viruses after 2h
50), 37 DEG C, 5%CO
2cultivate, twice is washed with PBS after 30h, 50 μ l/ hole anhydrous methanol fixed cell 10min, then 100 μ l/ hole PBS+0.5%Tween20+10%FBS37 DEG C closed 1h are added after washing twice with PBS, add the primary antibodie 37 DEG C effect 3h diluted in 100 μ l/ holes (1: 500), plank is cleaned 3 times with 0.5%PBST, add the two anti-anti-mouseimmunoglobulinG that 100 μ l/ holes (1: 2500) are diluted, 37 DEG C of effect 1h, plank is cleaned 3 times with 0.5%PBST, add 100 μ l/ hole OPD substrate color development at room temperature 5min, with 50 μ l/ hole 1MH
2sO
4termination reaction, on ELISA determinator, (490nM) reads the fluorescent value in every hole.More than test each concentration of inhibitor 4 holes, repeat 3 times.EC is calculated with GraphPadPrism5
50value.The EC of compounds X IV
50value is less than 1 μM.
Claims (9)
1. 2-piperidone base aldehydes enteric virus71 (EV71) HRV 3CP inhibitor, has compound or its optical isomer, the pharmacologically acceptable salt of structure as follows:
2. the application of inhibitor described in claim 1 in preparation treatment enterovirus infection disease medicament, wherein, described enterovirus comprises: CA, Coxsackie B virus, enteric virus71 (EV71).
3. the application of inhibitor described in claim 1 in the medicine of preparation treatment coronavirus infection disease, wherein, described coronavirus comprises: SARS virus.
4. the application of inhibitor described in claim 1 in the medicine that induces an illness of preparation treatment L-Cysteine HCL Anhydrous, wherein, described L-Cysteine HCL Anhydrous induces an illness and comprises: hand foot mouth disease, poliomyelitis, common cold, myocarditis, meningitis, hepatitis A.
5. a pharmaceutical composition, this pharmaceutical composition includes the inhibitor according to claim 1 of effective amount and its pharmaceutically acceptable carrier medium or auxiliary agent.
6. pharmaceutical composition according to claim 5, this pharmaceutical composition also comprises EV71 antiviral agent, and described EV71 antiviral agent is the anti-virus formulation being selected from 3D proteinase inhibitor and VP1 protein inhibitor.
7. the application of pharmaceutical composition described in claim 5 in preparation treatment enteric virus71 (EV71) medicine that catches.
8. the application of pharmaceutical composition described in claim 6 in preparation treatment enteric virus71 (EV71) antiviral that catches.
9. the application of pharmaceutical composition described in claim 5 in the medicine of preparation for the mammiferous EV71 virus infection for the treatment of.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110384897.9A CN103130710B (en) | 2011-11-29 | 2011-11-29 | Anti-enteric virus71 (EV71) hexanolactam aldehyde compound and its production and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110384897.9A CN103130710B (en) | 2011-11-29 | 2011-11-29 | Anti-enteric virus71 (EV71) hexanolactam aldehyde compound and its production and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103130710A CN103130710A (en) | 2013-06-05 |
| CN103130710B true CN103130710B (en) | 2015-12-16 |
Family
ID=48491214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110384897.9A Expired - Fee Related CN103130710B (en) | 2011-11-29 | 2011-11-29 | Anti-enteric virus71 (EV71) hexanolactam aldehyde compound and its production and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103130710B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9193767B2 (en) | 2011-03-30 | 2015-11-24 | Brown University | Enopeptins, uses thereof, and methods of synthesis thereto |
| WO2016037072A2 (en) * | 2014-09-04 | 2016-03-10 | Brown University | Enopeptin analogas and methods of use thereof |
| CN107459511B (en) * | 2016-06-02 | 2020-05-29 | 南开大学 | Anti-enterovirus 71(EV71) 4-iminooxazolidine-2-ketone compound and preparation method and application thereof |
| CN106883166A (en) * | 2017-02-13 | 2017-06-23 | 中国药科大学 | 4-（3- piperidyls）The preparation method of aniline and its tartrate |
| CN110105348A (en) * | 2019-03-08 | 2019-08-09 | 南开大学 | The preparation and purposes of novel michael acceptor class enteric virus71 type inhibitor |
| CN110354248A (en) * | 2019-04-26 | 2019-10-22 | 南开大学 | Application of the peptidomimetic aldehyde compound in preparation treatment swine fever virus (ASFV) infectious disease drug |
| US11124497B1 (en) | 2020-04-17 | 2021-09-21 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
| US11174231B1 (en) | 2020-06-09 | 2021-11-16 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| WO2023198067A1 (en) * | 2022-04-11 | 2023-10-19 | 上海科技大学 | Compound and application thereof in preparation of medicine for treating enterovirus-related diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1372566A (en) * | 1999-08-04 | 2002-10-02 | 阿格罗尼制药公司 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
-
2011
- 2011-11-29 CN CN201110384897.9A patent/CN103130710B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1372566A (en) * | 1999-08-04 | 2002-10-02 | 阿格罗尼制药公司 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103130710A (en) | 2013-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103145608B (en) | Anti-enteric virus71 (EV71) hexanolactam compounds and its production and use | |
| CN103130710B (en) | Anti-enteric virus71 (EV71) hexanolactam aldehyde compound and its production and use | |
| CN102838523A (en) | Anti-enterovirus 71 (EV71) valerolactam compounds, preparation method and uses thereof | |
| CN102526087B (en) | Application of nucleoside compound to preparation of medicament for treating enterovirus 71 (EV71) infectious disease | |
| CN110105348A (en) | The preparation and purposes of novel michael acceptor class enteric virus71 type inhibitor | |
| CN110041327A (en) | Pyridione derivatives, its composition and the application as anti-influenza virus medicament | |
| CN108473477A (en) | The pyrimidine of aryl substitution for being used in influenza infection | |
| CN103420942B (en) | Second, butyrylcholine esterase had dual restraining activities compound | |
| CN106883280B (en) | A kind of prodrug, preparation method, medical composition and its use | |
| CN106061975A (en) | Pyrazolo[1,5-a]pyrimidines as antiviral compounds | |
| CN103387601B (en) | Anti-dengue virus (DENV) heterocyclic peptide compounds and preparing methods and uses thereof | |
| BR112020023269A2 (en) | matrix metalloproteinase inhibitors (mmps) and methods of using the same | |
| CN107459511A (en) | Ketone compounds of 4 imino group oxazolidine of anti-enteric virus71 (EV71) 2 and its production and use | |
| TR201809418T4 (en) | Guanidinobenzoic acid ester compound. | |
| CN103848762B (en) | Prodrug of neuraminidase inhibitor and combinations thereof thing and purposes | |
| CN106687449B (en) | A kind of aminosulfonyl base class compound, preparation method and the usage | |
| CN104211666A (en) | 2,3-epoxy succinamide compound, preparation method and purpose thereof | |
| CN100560568C (en) | Cyclin imide peptidyl metalloprotease inhibitor and application thereof | |
| CN101541780A (en) | Fibrate carboxylate compounds, preparation methods and uses thereof | |
| CN116648240A (en) | Cyclic peptide virus protease inhibitor, preparation method thereof and application thereof in antiviral drugs | |
| CN104447481B (en) | Benzoic acid Thiourea resisiting influenza virus compound and its production and use | |
| CN103421083A (en) | Anti-dengue virus heterocycle peptide compounds having 1,2,3-triazole structure, preparation method and use thereof | |
| CN107827830B (en) | Oseltamivir derivative and preparation method and application thereof | |
| CA2596850A1 (en) | Medicament for genital herpes | |
| CN107074876B (en) | Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DD01 | Delivery of document by public notice |
Addressee: Nankai University Shang Luqing Document name: Notification of Passing Preliminary Examination of the Application for Invention |
|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 300071 Tianjin City, Nankai District Wei Jin Road No. 94 Applicant after: Nankai University Applicant after: Tsinghua University Applicant after: TIANJIN INTERNATIONAL JOINT ACADEMY OF BIOMEDICINE Address before: 300071 Tianjin City, Nankai District Wei Jin Road No. 94 Applicant before: Nankai University Applicant before: Tsinghua University Applicant before: Tianjin International Joint Academy High Throughput Molecule Pharmaceutical Screening Center |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151216 Termination date: 20171129 |